Detalhe da pesquisa
1.
Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper.
N Engl J Med
; 389(14): 1263-1272, 2023 Oct 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37792612
2.
Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial.
Lancet
; 403(10432): 1141-1152, 2024 Mar 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38461841
3.
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial.
Lancet
; 403(10432): 1153-1163, 2024 Mar 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38461843
4.
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.
N Engl J Med
; 384(3): 238-251, 2021 01 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-33332778
5.
REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19.
N Engl J Med
; 385(23): e81, 2021 12 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34587383
6.
Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19.
J Infect Dis
; 227(1): 23-34, 2022 12 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35895508
7.
Efficacy and Safety of Sarilumab in Hospitalized Patients With Coronavirus Disease 2019: A Randomized Clinical Trial.
Clin Infect Dis
; 75(1): e380-e388, 2022 08 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35219277
8.
Baseline Severe Acute Respiratory Syndrome Viral Load Is Associated With Coronavirus Disease 2019 Severity and Clinical Outcomes: Post Hoc Analyses of a Phase 2/3 Trial.
J Infect Dis
; 224(11): 1830-1838, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34496013
9.
Analysis of the Role of Plasma 25-Hydroxyvitamin D Levels in Survival Outcomes in Patients from the Phase III MPACT Trial of Metastatic Pancreatic Cancer.
Oncologist
; 26(4): e704-e709, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33345430
10.
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
N Engl J Med
; 377(14): 1345-1356, 2017 10 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28889792
11.
Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer.
Future Oncol
; 16(12): 749-762, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-32228198
12.
Association between depth of response and survival in patients with advanced-stage non-small cell lung cancer treated with first-line chemotherapy.
Cancer
; 125(14): 2394-2399, 2019 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30933354
13.
ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC).
Cancer
; 124(24): 4667-4675, 2018 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30383906
14.
Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).
Hepatology
; 63(5): 1430-41, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-26822022
15.
12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens.
Clin Infect Dis
; 62(12): 1489-96, 2016 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27025835
16.
All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study.
Liver Int
; 36(10): 1433-41, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27009831
17.
On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvir.
Liver Int
; 36(11): 1611-1618, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27188960
18.
Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis.
Liver Int
; 36(7): 954-62, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-26683763
19.
Effectiveness of Casirivimab and Imdevimab Antibody Combination in Immunocompromised Hospitalized Patients With Coronavirus Disease 2019: A Post Hoc Analysis in a Phase 1/2/3 Double-Blind Trial.
Open Forum Infect Dis
; 10(5): ofad211, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37229174
20.
Monoclonal antibodies against GFRα3 are efficacious against evoked hyperalgesic and allodynic responses in mouse join pain models but, one of these, REGN5069, was not effective against pain in a randomized, placebo-controlled clinical trial in patients with osteoarthritis pain.
Neurobiol Pain
; 14: 100136, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38099276